• Our Mission
    • Urgent Transformation
    • AAV-based Gene Therapies
    • Our Vision
  • Our Focus and Pipeline
    • Therapeutic Areas
    • Pipeline
  • Our People
    • A Team with Purpose
    • Executive Team
    • Board of Directors
  • News
  • Careers
  • Contact

News and updates

Catch up on the latest news from Jaguar Gene Therapy.

July 20, 2020

UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm

The pioneering collaboration completed the licensing of the first Apollo-supported project, a novel gene therapy programme developed at University College London (UCL)

September 26, 2019

Deerfield management brings together scientists, entrepreneurs and leading companies to form the New York-based healthcare innovation campus

$635 Million in Real Estate and Multi-Disciplinary Laboratory Infrastructure Will Combine With Multi-Billion Dollar Investments in Research to Transform the Battle Against Disease

Jaguar Gene Therapy, LLC is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Backed by Deerfield Management, a healthcare-specific investment firm, Jaguar brings streamlined R&D, manufacturing and clinical operations to accelerate development and potential approval of therapies for severe genetic diseases.

  • Privacy Notice
  • Terms of Service
© 2020-2021 Jaguar Gene Therapy, LLC All rights reserved.
  • LinkedIn